181 related articles for article (PubMed ID: 24439051)
1. Poly(ADP-ribose) polymerase inhibitor CEP-8983 synergizes with bendamustine in chronic lymphocytic leukemia cells in vitro.
Dilley RL; Poh W; Gladstone DE; Herman JG; Showel MM; Karp JE; McDevitt MA; Pratz KW
Leuk Res; 2014 Mar; 38(3):411-7. PubMed ID: 24439051
[TBL] [Abstract][Full Text] [Related]
2. Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells.
Modi P; Balakrishnan K; Yang Q; Wierda WG; Keating MJ; Gandhi V
Oncotarget; 2017 Mar; 8(10):16259-16274. PubMed ID: 28187444
[TBL] [Abstract][Full Text] [Related]
3. In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia.
Schwänen C; Hecker T; Hübinger G; Wölfle M; Rittgen W; Bergmann L; Karakas T
Leukemia; 2002 Oct; 16(10):2096-105. PubMed ID: 12357363
[TBL] [Abstract][Full Text] [Related]
4. The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity.
Miknyoczki S; Chang H; Grobelny J; Pritchard S; Worrell C; McGann N; Ator M; Husten J; Deibold J; Hudkins R; Zulli A; Parchment R; Ruggeri B
Mol Cancer Ther; 2007 Aug; 6(8):2290-302. PubMed ID: 17699724
[TBL] [Abstract][Full Text] [Related]
5. Activity of CEP-9722, a poly (ADP-ribose) polymerase inhibitor, in urothelial carcinoma correlates inversely with homologous recombination repair response to DNA damage.
Jian W; Xu HG; Chen J; Xu ZX; Levitt JM; Stanley JA; Yang ES; Lerner SP; Sonpavde G
Anticancer Drugs; 2014 Sep; 25(8):878-86. PubMed ID: 24714082
[TBL] [Abstract][Full Text] [Related]
6. PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia.
Herriott A; Tudhope SJ; Junge G; Rodrigues N; Patterson MJ; Woodhouse L; Lunec J; Hunter JE; Mulligan EA; Cole M; Allinson LM; Wallis JP; Marshall S; Wang E; Curtin NJ; Willmore E
Oncotarget; 2015 Dec; 6(41):43978-91. PubMed ID: 26539646
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.
Oplustilova L; Wolanin K; Mistrik M; Korinkova G; Simkova D; Bouchal J; Lenobel R; Bartkova J; Lau A; O'Connor MJ; Lukas J; Bartek J
Cell Cycle; 2012 Oct; 11(20):3837-50. PubMed ID: 22983061
[TBL] [Abstract][Full Text] [Related]
8. BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer.
Jacot W; Thezenas S; Senal R; Viglianti C; Laberenne AC; Lopez-Crapez E; Bibeau F; Bleuse JP; Romieu G; Lamy PJ
BMC Cancer; 2013 Nov; 13():523. PubMed ID: 24191908
[TBL] [Abstract][Full Text] [Related]
9. Akt inhibitor MK2206 selectively targets CLL B-cell receptor induced cytokines, mobilizes lymphocytes and synergizes with bendamustine to induce CLL apoptosis.
Ding W; Shanafelt TD; Lesnick CE; Erlichman C; Leis JF; Secreto C; Sassoon TR; Call TG; Bowen DA; Conte M; Kumar S; Kay NE
Br J Haematol; 2014 Jan; 164(1):146-50. PubMed ID: 24111951
[No Abstract] [Full Text] [Related]
10. Poly (ADP-ribose) polymerase inhibitors selectively induce cytotoxicity in TCF3-HLF-positive leukemic cells.
Piao J; Takai S; Kamiya T; Inukai T; Sugita K; Ohyashiki K; Delia D; Masutani M; Mizutani S; Takagi M
Cancer Lett; 2017 Feb; 386():131-140. PubMed ID: 27894958
[TBL] [Abstract][Full Text] [Related]
11. Sulfur and nitrogen mustards induce characteristic poly(ADP-ribosyl)ation responses in HaCaT keratinocytes with distinctive cellular consequences.
Mangerich A; Debiak M; Birtel M; Ponath V; Balszuweit F; Lex K; Martello R; Burckhardt-Boer W; Strobelt R; Siegert M; Thiermann H; Steinritz D; Schmidt A; Bürkle A
Toxicol Lett; 2016 Feb; 244():56-71. PubMed ID: 26383629
[TBL] [Abstract][Full Text] [Related]
12. Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer.
Michels J; Vitale I; Senovilla L; Enot DP; Garcia P; Lissa D; Olaussen KA; Brenner C; Soria JC; Castedo M; Kroemer G
Cell Cycle; 2013 Mar; 12(6):877-83. PubMed ID: 23428903
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells.
El-Mabhouh AA; Ayres ML; Shpall EJ; Baladandayuthapani V; Keating MJ; Wierda WG; Gandhi V
Blood; 2014 Jun; 123(24):3780-9. PubMed ID: 24747434
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide.
Tentori L; Ricci-Vitiani L; Muzi A; Ciccarone F; Pelacchi F; Calabrese R; Runci D; Pallini R; Caiafa P; Graziani G
BMC Cancer; 2014 Mar; 14():151. PubMed ID: 24593254
[TBL] [Abstract][Full Text] [Related]
15. A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells.
Senhaji Mouhri Z; Goodfellow E; Jean-Claude B
BMC Cancer; 2017 Aug; 17(1):540. PubMed ID: 28800752
[TBL] [Abstract][Full Text] [Related]
16.
Poh W; Dilley RL; Moliterno AR; Maciejewski JP; Pratz KW; McDevitt MA; Herman JG
Clin Cancer Res; 2019 Apr; 25(8):2513-2522. PubMed ID: 30692098
[TBL] [Abstract][Full Text] [Related]
17. Nitrogen mustard drug resistant B-cell chronic lymphocytic leukemia as an in vivo model for crosslinking agent resistance.
Bramson J; McQuillan A; Aubin R; Alaoui-Jamali M; Batist G; Christodoulopoulos G; Panasci LC
Mutat Res; 1995 May; 336(3):269-78. PubMed ID: 7739615
[TBL] [Abstract][Full Text] [Related]
18. DNA-Dependent protein kinase activity correlates with clinical and in vitro sensitivity of chronic lymphocytic leukemia lymphocytes to nitrogen mustards.
Muller C; Christodoulopoulos G; Salles B; Panasci L
Blood; 1998 Oct; 92(7):2213-9. PubMed ID: 9746757
[TBL] [Abstract][Full Text] [Related]
19. A subset of chronic lymphocytic leukemia patients display reduced levels of PARP1 expression coupled with a defective irradiation-induced apoptosis.
Bacalini MG; Tavolaro S; Peragine N; Marinelli M; Santangelo S; Del Giudice I; Mauro FR; Di Maio V; Ricciardi MR; Caiafa P; Chiaretti S; Foà R; Guarini A; Reale A
Exp Hematol; 2012 Mar; 40(3):197-206.e1. PubMed ID: 22120020
[TBL] [Abstract][Full Text] [Related]
20. CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia.
Montraveta A; Lee-Vergés E; Roldán J; Jiménez L; Cabezas S; Clot G; Pinyol M; Xargay-Torrent S; Rosich L; Arimany-Nardí C; Aymerich M; Villamor N; López-Guillermo A; Pérez-Galán P; Roué G; Pastor-Anglada M; Campo E; López-Guerra M; Colomer D
Oncotarget; 2016 Feb; 7(5):5507-20. PubMed ID: 26701728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
